AKT1 and neoplasm: AKT is regarded as an appropriate target for cancer treatment because of its propensity to accelerate tumor progression and resistance to a variety of chemotherapeutic agents (Ma et al., 2019; Gallyas et al., 2020; Sobočan et al., 2020).